Compare Flux Power Holdings Inc (FLUX) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Flux Power Holdings Inc vs Novartis AG — how do they compare? Flux Power Holdings Inc trades at $0.58 (market cap $11.23M), while Novartis AG trades at $152.33 (market cap $295.37B). The key difference: Novartis AG is far larger — about 26301.9× Flux Power Holdings Inc's market cap, and Novartis AG pays a 3.07% dividend while Flux Power Holdings Inc pays none. Which is the better fit depends on your goals.
| FLUX | NVS | |
|---|---|---|
Market Cap | $11.23M | $295.37B |
Sector | Utilities | Health |
52-Week High | $6.66 | $168.62 |
52-Week Low | $0.51 | $119.31 |
Enterprise Value | $17.39M | $336.69B |
Dividend Yield | — | 3.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLUX trades at $0.535, up 0.66% with a bearish technical signal despite 100% analyst buy ratings. The company reported mixed earnings with Q4 2025 beating expectations but Q1 2026 missing, while revenue declined from $66M in 2025 to $51M in 2026. Recent product launches like SkyEMS 3.0 and executive appointments aim to drive growth amid negative profitability metrics.
The outlook remains challenged by persistent net losses and negative ROE, though low P/S ratio and strong analyst support offer potential upside if operational improvements materialize. Key risks include cash flow volatility and competitive pressure in the clean energy sector.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Flux Power Holdings Inc
Flux Power designs and manufactures lithium-ion battery packs for industrial vehicles. Its sustainable energy solutions power material handling equipment like forklifts and airport ground support vehicles.
Read more on FLUX →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
